US Pharma MarketingPfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi
The FDA has expanded the label for Pfizer’s subcutaneous hemop The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation…
The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.
Source: FiercePharma